SpringWorks Therapeutics Got Notice Of Termination Of Amended & Restated Collaboration And License Agreement, Dated Sept 6, 2022, Between Co & GSK
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics received a notice of termination for its amended and restated collaboration and license agreement with GSK, dated September 6, 2022, according to an SEC filing.
June 07, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GSK terminated its collaboration and license agreement with SpringWorks Therapeutics. This move might have a neutral to slightly positive impact on GSK's stock as it could be reallocating resources to more promising projects.
The termination of the agreement with SpringWorks Therapeutics might allow GSK to reallocate resources to other projects, which could be seen as a neutral to slightly positive move for the company.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
SpringWorks Therapeutics received a notice of termination for its collaboration and license agreement with GSK. This could negatively impact SpringWorks' stock in the short term due to potential disruptions in their development pipeline and loss of anticipated revenue.
The termination of the agreement with GSK could lead to disruptions in SpringWorks' development pipeline and a loss of anticipated revenue, which is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100